Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194762 | 1.00 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2197301 | 0.81 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2197387 | 0.81 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12429278 | 0.79 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2198306 | 0.78 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2198315 | 0.78 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2201092 | 0.78 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2204343 | 0.72 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2703711 | 0.71 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2703714 | 0.71 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152713-B1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARM INC (US) | 2011-09-07 | — | — | EP | claimed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | claimed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| EP-2152713-B1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARM INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2152713-A1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008147800-A1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147800-A1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.